Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer: Final appraisal document

In DRAFT guidance, NICE has recommended entrectinib, as an option for treating ROS1-positive advanced non-small-cell lung cancer in adults who have not had ROS1 inhibitors, providing it is supplied according to the commercial arrangement.

Source:

National Institute for Health and Care Excellence